Anthos Therapeutics' Novel Dual-Acting Factor XI/XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation

Liverpool vs Brentford LIVE: Premier League team news and line-ups as Mohamed Salah and Cody Gakpo start

What’s the Kennection? #88

Five Things to Watch This Week

A $20 Billion Week Marks Reopening of Market for EM Borrowers

Eskom Ramps Up Power Cuts as it Releases Schedule for the Week

Is Chelsea v Manchester City on TV? Channel, time and how to watch Premier League fixture

Erik ten Hag gives update on injured Man Utd duo after Luton win

What time and do the Chiefs play today, Week 10?

Auto-Parts Maker Continental May Cut 5,500 Jobs

Ugandan army officers sacked for cowardice in attack on Somalia's Bulo Marer Atmis base

Taylor Swift fans go wild after first public kiss with Travis Kelce